ERBB2 and breast carcinoma: However, HER2‐low cancers, defined as immunohistochemistry (IHC) 1+ or 2+ and negative in situ hybridization tests, represent 45%–55% of breast cancer patients and are unlikely to benefit from conventional HER2‐targeted drugs.